ArticleAmerican journal of cancer research2021

BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression.

Weiqiong Zuo et al.PubMed ↗Full text ↗

No numbers read from the abstract.